A Study of Belantamab Mafodotin to Investigate Safety, Tolerability, Pharmacokinetics, Immunogenicity and Clinical Activity in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)
A Phase I Open-label, Dose Escalation Study to Investigate the Safety, Tolerability, Pharmacokinetics, Immunogenicity and Clinical Activity of the Antibody Drug Conjugate GSK2857916 in Chinese Participants With Relapsed/Refractory Multiple Myeloma Who Have Failed At Least Two Lines of Previous Treatment, Containing an Alkylator, a Proteasome Inhibitor and an Immunomodulatory Agent
Sponsor: GlaxoSmithKline
Listed as NCT04177823, this PHASE1 trial focuses on Multiple Myeloma and remains completed. Sponsored by GlaxoSmithKline, it has been updated 14 times since 2019, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
14 versions recorded-
Apr 2025 — Present [monthly]
Completed PHASE1
-
Sep 2024 — Apr 2025 [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
May 2024 — Jul 2024 [monthly]
Completed PHASE1
-
Mar 2022 — May 2024 [monthly]
Completed PHASE1
Status: Active Not Recruiting → Completed
▶ Show 9 earlier versions
-
Feb 2022 — Mar 2022 [monthly]
Active Not Recruiting PHASE1
-
Nov 2021 — Feb 2022 [monthly]
Active Not Recruiting PHASE1
-
Jan 2021 — Nov 2021 [monthly]
Active Not Recruiting PHASE1
-
Sep 2020 — Jan 2021 [monthly]
Active Not Recruiting PHASE1
Status: Recruiting → Active Not Recruiting
-
Jul 2020 — Sep 2020 [monthly]
Recruiting PHASE1
-
Jun 2020 — Jul 2020 [monthly]
Recruiting PHASE1
-
Mar 2020 — Jun 2020 [monthly]
Recruiting PHASE1
-
Feb 2020 — Mar 2020 [monthly]
Recruiting PHASE1
Status: Not Yet Recruiting → Recruiting
-
Dec 2019 — Feb 2020 [monthly]
Not Yet Recruiting PHASE1
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- GlaxoSmithKline
For direct contact, visit the study record on ClinicalTrials.gov .